New FDA-Approved Gastro-Esophageal Cancer Breakthrough: How ZIIHERA Works; Oncologist Explains

What is ZIIHERA, and how is this newly FDA-approved targeted therapy transforming the treatment of advanced HER2-positive gastroesophageal cancer?

In this episode 168 of DoctorPodcasts: Cykiert Files, host Dr. Robert Cykiert is joined by two world-renowned oncology experts: • Dr. Geoffrey Ku – Associate Attending Physician, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) & Phase 3 trial investigator. • Dr. Robert Iannone – Executive Vice President, Global Head of R&D, and Chief Medical Officer at Jazz Pharmaceuticals.

Together, they break down the groundbreaking science behind ZIIHERA, the landmark HORIZON-GEA-01 Phase 3 trial results, managing treatment side effects (including diarrhea prophylaxis), biomarker testing (HER2 & PD-L1), and what this means for patients with metastatic and locally advanced esophageal, GE junction, and gastric adenocarcinoma cancers.

📌 In This Episode, You’ll Learn: • What gastroesophageal adenocarcinoma (GEJ cancer) is and key risk factors (acid reflux, Barrett’s esophagus, H. pylori). • How ZIIHERA’s unique bispecific HER2 antibody mechanism differs from standard therapies like Herceptin (trastuzumab). • Key survival and progression-free survival findings from the HORIZON-GEA-01 Phase 3 study. • Why ZIIHERA combined with immunotherapy benefits patients regardless of PD-L1 status. • Essential clinical guidance on managing and preventing GI side effects. • Why comprehensive biomarker and HER2 testing is vital for every patient.

⏱️ TIMELINE / CHAPTERS:

00:00 - Introduction to Gastroesophageal Cancer & ZIIHERA

00:43 - Introducing Dr. Geoffrey Ku (MSKCC) & Dr. Robert Iannone (Jazz Pharmaceuticals)

02:16 - What is Gastroesophageal Adenocarcinoma (GE Junction & Stomach Cancer)?

03:27 - Risk Factors: Acid Reflux, Barrett’s Esophagus, Obesity & H. Pylori

06:43 - Why Esophageal and Stomach Cancers Are Often Diagnosed Late

09:17 - Understanding HER2-Positive Cancer & Key Biomarkers (PD-L1, MMR, Claudin 18.2)

12:25 - Evolution of 1st-Line Treatment: Chemo, Trastuzumab & Immunotherapy

14:06 - How ZIIHERA (Zanidatamab) Was Developed & Mechanism of Action

17:03 - Biliary Tract Cancer Approval to Gastroesophageal Phase 3 Trials

19:30 - HORIZON-GEA-01 Phase 3 Trial Design & FDA Approval Indications

20:56 - Efficacy Across PD-L1 Positive and Negative Patients

22:20 - Metastatic vs. Locally Advanced Disease & Potential Curative Setting

26:13 - Safety Profile & Managing Side Effects (Diarrhea Prophylaxis Protocols)

31:08 - Cardiac Monitoring & Drug Tolerability

31:47 - Dosing, Administration Route & Treatment Duration

33:28 - Overall Survival & Progression-Free Survival Data Breakdown

39:16 - Patient Quality of Life During Treatment

40:17 - Encouragement for Patients & Families Considering Targeted Therapy

44:06 - Nationwide Availability & Global Regulatory Status (Project Orbis)

46:11 - The Critical Importance of Routine HER2 Biomarker Testing

48:11 - Future Applications of ZIIHERA & Jazz Pharmaceuticals Oncology Pipeline

51:09 - Concluding Remarks & Summary

🔔 Please subscribe to DoctorPodcasts: Cykiert Files for expert discussions on medical breakthroughs, clinical trials, and healthcare innovations.

Disclaimer: This video podcast is for educational and informational purposes only and does not constitute personalized medical advice. Please consult your physician or qualified healthcare provider regarding specific medical conditions or treatments.

#EsophagealCancer #ZIIHERA #StomachCancer #Oncology #CancerResearch #HER2Positive #Immunotherapy #CancerBreakthrough #MedicalPodcast #JazzPharmaceuticals #Cykiert #DoctorPodcasts